YB
YK Bioventures is a venture capital firm that primarily invests in early-stage companies within the healthcare and technology sectors, with a strong focus on biotechnology, medicine, and drug discovery across the U.S.. Their strategy involves providing not only capital but also industry experience and connections to their portfolio companies.
100% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (67% of deals). Average disclosed round size is $42.4M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Think Bioscience | Series A | $55M | Jan 2026 |
| PPsiThera | Series A | $47.5M | Dec 2025 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
| Think Bioscience | Seed | $6M | May 2024 |
 Tempo Therapeutics | Series A | $12M | Mar 2024 |
 Pelage Pharmaceuticals | Series A | $14M | Feb 2024 |
Top Co-Investors
Innovation Endeavors1 shared
Janus Henderson Investors1 shared
MBX Capital1 shared
AV8 Ventures1 shared
Buff Gold Ventures1 shared
Samsara BioCapital1 shared
Lightstone Ventures1 shared
GV (Google Ventures)1 shared
Main Street Advisors1 shared
Visionary Ventures1 shared
Bessemer Venture Partners1 shared
Invus1 shared
RA Capital Management1 shared
Atlas Venture1 shared
Lightspeed Venture Partners1 shared
Pfizer Ventures1 shared
Surveyor Capital1 shared
Last updated: 16 April 2026